MACROBID (nitrofurantoin monohydrate/macrocrystalline) by Almatica Pharma is mechanism of action the mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. Approved for pyelonephritis, perinephric abscesses. First approved in 1991.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
MACROBID is an oral nitrofuran antibacterial indicated for pyelonephritis and perinephric abscesses. It works by being reduced by bacterial flavoproteins into reactive intermediates that inhibit protein synthesis, energy metabolism, DNA/RNA synthesis, and cell wall synthesis. The broad-based mechanism of action results in bactericidal activity in urine with minimal acquired resistance.
Product is approaching loss of exclusivity with modest Medicare spending ($64K, 483 claims in 2023), indicating a niche mature brand facing revenue contraction and potential team restructuring.
Mechanism of Action The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other macromolecules. As a result of such…
Nitrofuran Antibacterial
Worked on MACROBID at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moMACROBID offers limited career growth opportunity as a mature, LOE-approaching generic asset with minimal linked job openings and declining commercial investment. Roles on this product focus on generic transition management, cost optimization, and supply chain efficiency rather than innovation or market expansion.